Compare Medpace Holdings Inc (MEDP) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while State Street SPDR S&P Homebuilders ETF trades at $94.77 (market cap $1.49B). The key difference: Medpace Holdings Inc is far larger — about 11.3× State Street SPDR S&P Homebuilders ETF's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| MEDP | XHB | |
|---|---|---|
Market Cap | $16.82B | $1.49B |
Volume | 223,093 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $630.19 | $121.36 |
52-Week Low | $393.42 | $94.77 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
XHB (SPDR S&P Homebuilders ETF) trades at $95.66, up 0.81% with a bearish technical signal from moving averages. The ETF faces headwinds from rising mortgage rates above 7% but shows potential as homebuilder valuations signal historical buying opportunities. Recent housing data shows mixed signals with new home sales rising 1.6% in June while existing home sales declined 2.4%.
The ETF presents a contrarian opportunity as battered homebuilder stocks may rebound if housing affordability improves. Key risks include persistent high mortgage rates and economic uncertainty. Institutional activity shows mixed signals with Greenland Capital's $17.33 million investment contrasting CoreCap's 99.3% position reduction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
